EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Endpoints and Design for Clinical Trials in USH2A -Related Retinal Degeneration: Results and Recommendations From the RUSH2A Natural History Study

Maureen G Maguire, David G Birch, Jacque L Duncan, Allison R Ayala, Lauren N Ayton, Janet K Cheetham, Peiyao Cheng, Todd A Durham, Frederick L Ferris, Carel B Hoyng, Rachel M Huckfeldt, Glenn J Jaffe und 11 weitere

Translational Vision Science & Technology · 09.10.2024 · 13 (10) · 15

DOI: 10.1167/tvst.13.10.15 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Vision Science & Technology, erschienen am 09.10.2024. Verfasst von Maureen G Maguire und 22 weiteren Autor:innen. Beteiligte Einrichtung: Jaeb Center for Health Research, Tampa, FL, USA. Hauptthemen laut MEDLINE: Visual Acuity, Visual Fields, Visual Field Tests, Extracellular Matrix Proteins. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NEI NIH HHS, Foundation Fighting Blindness.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate functional and structural assessments as endpoints for clinical trials for USH2A-related retinal degeneration.

Methods

People with biallelic disease-causing variants in USH2A, visual acuity ≥ 20/80, and visual field ≥ 10° diameter were enrolled in a 4-year, natural history study. Participants underwent static perimetry, microperimetry, visual acuity, fullfield stimulus testing (FST), and optical coherence tomography annually. Rates of change estimated from mixed-effects linear models and percentages of eyes with changes exceeding the coefficient of repeatability (CoR) or thresholds conforming with U.S. Food and Drug Administration (FDA) guidelines were evaluated.

Results

Rates of change were generally more sensitive to change than proportions of eyes exceeding a threshold such as the CoR. Baseline ellipsoid zone area ≥ 3 mm2 was necessary to detect change. Mean sensitivity and volumetric hill of vision measures on static perimetry had similar properties and were the most sensitive to changes of the continuous measures. The highest 4-year proportions of eyes exceeding the CoR were from FST testing (47%) and microperimetry (32%). Specification of loci as functional transition points (FTPs) resulted in 45% (static perimetry) and 46% (microperimetry) at 4 years, meeting FDA guidelines for progression.

Conclusions

Rate of change of mean sensitivity on static perimetry was a sensitive perimetric continuous measure. Percentages of within-eye change were largest with FST testing and microperimetry. FTPs appear to be particularly sensitive to change. These results affect clinical trial design for USH2A-related retinal degeneration. Translational Relevance: Analyses of natural history data from the Rate of Progression in USH2A-Related Retinal Degeneration (RUSH2A) study can inform eligibility criteria and endpoints for clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Visual AcuityVisual FieldsVisual Field TestsExtracellular Matrix ProteinsRetinal DegenerationTomography, Optical CoherenceClinical Trials as TopicHumansFemaleMaleAdultMiddle AgedYoung AdultAgedResearch DesignAdolescentUsher Syndromes

Substanzen

USH2A protein, humanExtracellular Matrix Proteins

Autor:innen und Institutionen

  • Jaeb Center for Health Research, Tampa, FL, USA.
  • Retina Foundation of the Southwest, Dallas, TX, USA.
  • University of California, San Francisco, San Francisco, CA, USA.
  • University of Melbourne, and Centre for Eye Research Australia, East Melbourne, VIC, Australia.
  • Foundation Fighting Blindness, Columbia, MD, USA.
  • Ophthalmic Research Consultants, Waxhaw, NC, USA.

Förderung

  • NEI NIH HHS
  • Foundation Fighting Blindness

Zitieren

APA

Maguire, M. G., Birch, D. G., Duncan, J. L., Ayala, A. R., Ayton, L. N., Cheetham, J. K., Cheng, P., Durham, T. A., Ferris, F. L., Hoyng, C. B., Huckfeldt, R. M., Jaffe, G. J., Kay, C., Lad, E. M., Leroy, B. P., Liang, W., McDaniel, L. S., Melia, M., Michaelides, M., …, & REDI Working Group and the Foundation Fighting Blindness Clinical Consortium Investigator Group (2024). Endpoints and Design for Clinical Trials in USH2A -Related Retinal Degeneration: Results and Recommendations From the RUSH2A Natural History Study. Translational Vision Science & Technology, 13(10), 15. https://doi.org/10.1167/tvst.13.10.15

Vancouver

Maguire MG, Birch DG, Duncan JL, Ayala AR, Ayton LN, Cheetham JK, et al. Endpoints and Design for Clinical Trials in USH2A -Related Retinal Degeneration: Results and Recommendations From the RUSH2A Natural History Study. Translational Vision Science & Technology. 2024;13(10):15. doi:10.1167/tvst.13.10.15

BibTeX
@article{Maguire2024,
  author = {Maguire, Maureen G and Birch, David G and Duncan, Jacque L and Ayala, Allison R and Ayton, Lauren N and Cheetham, Janet K and Cheng, Peiyao and Durham, Todd A and Ferris, Frederick L and Hoyng, Carel B and Huckfeldt, Rachel M and Jaffe, Glenn J and Kay, Christine and Lad, Eleonora M and Leroy, Bart P and Liang, Wendi and McDaniel, Lee S and Melia, Michele and Michaelides, Michel and Pennesi, Mark E and Sahel, José-Alain and Samarakoon, Lassana and REDI Working Group and the Foundation Fighting Blindness Clinical Consortium Investigator Group, REDI Working Group and the Foundation Fighting Blindness Clinical Consortium Investigator Group},
  title = {Endpoints and Design for Clinical Trials in USH2A -Related Retinal Degeneration: Results and Recommendations From the RUSH2A Natural History Study},
  journal = {Translational Vision Science & Technology},
  year = {2024},
  volume = {13},
  number = {10},
  pages = {15},
  doi = {10.1167/tvst.13.10.15}
}
Kostenlos starten →